Abstract | AIM: MATERIALS & METHODS: Using selective TORC1/2 inhibitors, rapamycin and PP242, we assessed their effect on the growth of CRC cells in vitro and tumor growth in vivo. RESULTS: CONCLUSION: Our study suggests rapamycin and PP242 may be a useful therapeutic agent and inhibiting mTOR signaling pathway represents a new targeted therapy for CRC.
|
Authors | Jie Zhang, Wen Jiang, Wei Liu, Juan-Juan Wu, Lei Song, Ji-Xian Cheng, Ming Yao, Li-Ping Yang, Deng-Fu Yao |
Journal | Future oncology (London, England)
(Future Oncol)
Vol. 12
Issue 4
Pg. 515-24
(Feb 2016)
ISSN: 1744-8301 [Electronic] England |
PMID | 26776341
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents
- Indoles
- Multiprotein Complexes
- Protein Kinase Inhibitors
- Purines
- Doxorubicin
- Mechanistic Target of Rapamycin Complex 1
- Mechanistic Target of Rapamycin Complex 2
- TOR Serine-Threonine Kinases
- PP242
- Sirolimus
|
Topics |
- Animals
- Antineoplastic Agents
(pharmacology)
- Apoptosis
(drug effects)
- Cell Line, Tumor
- Cell Proliferation
(drug effects)
- Colorectal Neoplasms
(drug therapy, metabolism, pathology)
- Disease Models, Animal
- Doxorubicin
(pharmacology)
- Humans
- Indoles
(pharmacology)
- Mechanistic Target of Rapamycin Complex 1
- Mechanistic Target of Rapamycin Complex 2
- Mice
- Multiprotein Complexes
(antagonists & inhibitors)
- Protein Kinase Inhibitors
(pharmacology)
- Purines
(pharmacology)
- Signal Transduction
(drug effects)
- Sirolimus
(pharmacology)
- TOR Serine-Threonine Kinases
(antagonists & inhibitors)
- Tumor Stem Cell Assay
- Xenograft Model Antitumor Assays
|